Imbruvica
Blood cancers
CommercialActive
Key Facts
About Royalty Pharma
Founded in 1996, Royalty Pharma pioneered the royalty pharma asset class by providing non-dilutive capital to pharmaceutical innovators. The company has deployed over $19 billion to acquire royalty interests in leading medicines across multiple therapeutic areas. As a publicly-traded company on NASDAQ, Royalty Pharma generates revenue from royalty payments on successful drugs while helping fund the next generation of medical breakthroughs.
View full company profileOther Blood cancers Drugs
| Drug | Company | Phase |
|---|---|---|
| Calquence (acalabrutinib) | AstraZeneca | Approved |
| Imbruvica (ibrutinib) | Johnson & Johnson | Approved |
| Bendeka/Treanda (bendamustine) | Teva Pharmaceutical Industries | Commercial |
| Internal Blood Cancer Program(s) | Chimera Bioengineering | Pre-clinical |